Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. The increasing FDA approvals for conjugate vaccines are expected to drive market growth.
4.1.2. Restraints:
4.1.2.1. Fewer side effects of the conjugate vaccine are expected to hamper the market growth.
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Forces
5.2. Supply Chain
5.3. Pricing Analysis
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Product Type
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
7.1.2. Market Attractiveness Index, By Product Type
7.2. Monovalent Conjugate Vaccines*
7.2.1.1. Introduction
7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Multivalent Conjugate Vaccine
8. By Disease Indication
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication
8.1.2. Market Attractiveness Index, By Disease Indication
8.2. Pneumococcal*
8.2.1.1. Introduction
8.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Influenza
8.4. Meningococcal
8.5. Others
9. By Pathogen Type
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Type
9.1.2. Market Attractiveness Index, By Pathogen Type
9.2. Bacterial*
9.2.1.1. Introduction
9.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Viral
10. By Patient Type
10.1. Introduction
10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Patient Type
10.1.2. Market Attractiveness Index, By Patient Type
10.2. Pediatric*
10.2.1.1. Introduction
10.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
10.3. Adults
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication
11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Type
11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Patient Type
11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication
11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Type
11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Patient Type
11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. U.K.
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication
11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Type
11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Patient Type
11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication
11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Type
11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Patient Type
11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication
11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Type
11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Patient Type
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. GlaxoSmithKline plc.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. Merck & Co. Inc.
13.3. Fablife
13.4. SutroVax Inc.
13.5. Sanofi Pasteur SA.
13.6. Pfizer
13.7. Sinovac Biotech Ltd.
13.8. IDT Biologics GmbH
13.9. GreenSignal Bio Pharma Limited
13.10. Taj Pharmaceuticals Limited
13.11. Bavarian Nordic
LIST NOT EXHAUSTIVE
14. Global Conjugate Vaccine Market– DataM
14.1. Appendix
14.2. About Us
14.3. Contact Us